RenovoRx
RNXT • NASDAQ
RenovoRx is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Shaun R. Bagai, with a market cap of $53.4M.
CEOShaun R. Bagai
Next Earnings
Upcoming earnings announcement for RenovoRx
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.08
Revenue Estimate
$697.6K
Earnings History
Past 11 earnings reports for RenovoRx
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | Q3 2025 | -$0.08Est: -$0.08 | 0.0% | $266.0KEst: $346.4K | -23.2% |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.08Est: -$0.08 | 0.0% | $422.0KEst: $288.4K | +46.3% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.08Est: -$0.08 | 0.0% | $197.0KEst: $183.3K | +7.5% | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$0.12Est: -$0.10 | -20.0% | $43.0KEst: $167.5K | -74.3% | — |
| Nov 13, 2024 | Q3 2024 | -$0.10Est: -$0.12 | +16.7% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.10Est: -$0.10 | 0.0% | - | — | 10-Q |
| May 10, 2024 | Q1 2024 | -$0.07Est: -$0.16 | +56.3% | - | — | 10-Q |
| Apr 1, 2024 | Q4 2023 | -$0.30Est: -$0.30 | 0.0% | - | — | — |
| Nov 14, 2023 | Q3 2023 | -$0.13Est: -$0.30 | +56.7% | - | — | — |
| Aug 17, 2023 | Q2 2023 | -$0.22Est: -$0.25 | +12.0% | - | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.36Est: -$0.25 | -44.0% | - | — | 10-Q |